We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$122M
Cap. Flow
-$172M
Cap. Flow %
-6.22%
Top 10 Hldgs %
38.62%
Holding
217
New
37
Increased
33
Reduced
47
Closed
5

Top Buys

Rank Stock Value
1
ZTS icon
Zoetis
ZTS
+$17M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.8M
3
NVO
Novo Nordisk
NVO
+$8.1M
4
ELV icon
Elevance Health
ELV
+$7.92M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.37M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$42.7M
2
PFE icon
Pfizer
PFE
+$40.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$30.9M
4
UNH icon
UnitedHealth
UNH
+$21M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Real Estate 2.75%
3 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
126
Ardelyx
ARDX
$1.25B
$2.78M 0.1%
639,370
– –
TRIL
127
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.72M 0.1%
468,399
– –
HSIC icon
128
Henry Schein
HSIC
$9.7B
$2.67M 0.1%
40,035
– –
PRGO icon
129
Perrigo
PRGO
$1.43B
$2.64M 0.1%
37,300
– –
AGIO icon
130
Agios Pharmaceuticals
AGIO
$1.95B
$2.61M 0.09%
33,870
+31,060
+1,105% +$2.5M
DERM
131
DELISTED
Dermira, Inc.
DERM
$2.55M 0.09%
234,200
– –
MYOK
132
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$2.52M 0.09%
+38,600
New +$2.27M
CHRS icon
133
Coherus Oncology
CHRS
$227M
$2.47M 0.09%
149,820
-91,023
-38% -$1.61M
INVA icon
134
Innoviva
INVA
$1.57B
$2.46M 0.09%
161,603
– –
LGND icon
135
Ligand Pharmaceuticals
LGND
$5.94B
$2.45M 0.09%
+14,331
New +$2.16M
EDIT icon
136
Editas Medicine
EDIT
$413M
$2.44M 0.09%
76,668
-61,133
-44% -$1.98M
IOVA icon
137
Iovance Biotherapeutics
IOVA
$2.09B
$2.44M 0.09%
216,908
+183,513
+550% +$2.6M
GHDX
138
DELISTED
Genomic Health, Inc.
GHDX
$2.44M 0.09%
+34,740
New +$2.03M
EVH icon
139
Evolent Health
EVH
$358M
$2.39M 0.09%
84,300
-38,200
-31% -$911K
AERI
140
DELISTED
Aerie Pharmaceuticals
AERI
$2.39M 0.09%
+38,770
New +$2.49M
TTPH
141
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.37M 0.09%
42,966
– –
WHWK
142
Whitehawk Therapeutics
WHWK
$190M
$2.36M 0.09%
51,000
– –
AKBA icon
143
Akebia Therapeutics
AKBA
$362M
$2.35M 0.09%
266,612
– –
PTCT icon
144
PTC Therapeutics
PTCT
$6.26B
$2.27M 0.08%
+48,390
New +$2M
PTGX icon
145
Protagonist Therapeutics
PTGX
$8.92B
$2.25M 0.08%
219,042
– –
CLVS
146
DELISTED
Clovis Oncology, Inc.
CLVS
$2.21M 0.08%
75,400
– –
IQV icon
147
IQVIA
IQV
$39.1B
$2.18M 0.08%
+16,800
New +$2.02M
XRAY icon
148
Dentsply Sirona
XRAY
$2.75B
$2.17M 0.08%
+57,600
New +$2.4M
RGEN icon
149
Repligen
RGEN
$7.03B
$2.15M 0.08%
+38,700
New +$1.99M
MTD icon
150
Mettler-Toledo International
MTD
$27.9B
$2.13M 0.08%
+3,500
New +$2.06M
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Tekla Capital Management held 217 positions worth $2.76B, up 4.6% from $2.64B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management withdrew a net $172M in Q3 2018, closing 5 positions and reducing 47 holdings. Its most notable exit was Welltower Inc., an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Quest Diagnostics worth $4.21M.

  • Tekla Capital Management's largest Q3 2018 buy was Quest Diagnostics: 39,000 shares worth $4.21M.
  • Tekla Capital Management added most to Zoetis in Q3 2018, an estimated $17M increase.
  • Tekla Capital Management's biggest Q3 2018 reduction was Merck, cutting an estimated $42.7M.
  • Tekla Capital Management fully exited Welltower Inc. in Q3 2018, selling an estimated $11.9M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.76B portfolio in Q3 2018.
  • Tekla Capital Management opened 37 new positions and closed 5 in Q3 2018.
  • Tekla Capital Management's portfolio value rose 4.6% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.